Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications.

Rexer BN, Arteaga CL
Cancer Res. 2013 73 (13): 3817-20

PMID: 23794708 · PMCID: PMC3702635 · DOI:10.1158/0008-5472.CAN-13-0687

The combination of a PI3K inhibitor with trastuzumab has been shown to be effective at overcoming trastuzumab resistance in models of HER2(+) breast cancer by inhibiting HER2-PI3K-FOXO-survivin signaling. In this review the potential clinical implications of these findings are discussed.

©2013 AACR.

MeSH Terms (10)

Antineoplastic Agents Breast Neoplasms Clinical Trials as Topic Drug Resistance, Neoplasm Female Humans Molecular Targeted Therapy Phosphatidylinositol 3-Kinases Receptor, ErbB-2 Signal Transduction

Connections (3)

This publication is referenced by other Labnodes entities:

Links